Biotech

All Articles

8 months after a $213M fundraise, gene editor Volume makes cuts

.After rearing $213 thousand in 2023-- among the year's largest private biotech rounds-- Volume Bios...

BioMarin develops officer team with biotech veterinarians-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of significant leadership hirings, shootings...

Biopharma Q2 VC hit highest level since '22, while M&ampA decreased

.Equity capital backing into biopharma rose to $9.2 billion throughout 215 handle the 2nd quarter of...

Bicara, Zenas seek IPOs to drive late-phase resources towards market

.Bicara Rehabs and Zenas Biopharma have supplied new inspiration to the IPO market with filings that...

Genentech to shut cancer cells immunology investigation division

.Genentech will certainly shut its cancer cells immunology investigation division, and system mind a...

Kezar drops sound tumor yet to show its worth in phase 1 trial

.Kezar Lifestyle Sciences is falling its own dim period 1 sound tumor medicine as the biotech goes a...

Acelyrin goes down izokibep, dismisses 3rd of staff

.Regardless of izokibep maintaining its newly found winning streak in the clinic, Acelyrin is no lon...

Rivus' phase 2 obesity-related heart failure test attacks endpoint

.Rivus Pharmaceuticals has actually plumped up the prospects of its own fat-busting, muscle-sparing ...

Ovid halts preclinical job, IV course after soticlestat fall short

.Ovid Therapy currently disclosed last month that it was trimming its own head count as the firm get...

Eli Lilly opens $700M nucleic acid R&ampD center in Boston ma Seaport

.Eli Lilly has opened a $700 thousand R&ampD facility in the Boston Port, enhancing its RNA and also...